A government expert panel has reportedly approved a vaccine developed by AstraZeneca and Oxford University for emergency use in India to provide immunity against coronovirus disease (Kovid-19). According to the news agency Reuters, a Subject Expert Committee to set up the Kovid-19 vaccine proposals by the Drugs Controller General of India (DCGI), recommended the Emergency Use Authority to AstraZeneca vaccine AZ121222, which is referred to as Kovild in India Dubbed into.
AstraZeneca had signed an agreement with the Serum Institute of India (SII) to produce 1 billion doses of its experimental vaccine for low and middle income countries. The Pune-based company has sought an Emergency Use Authority for the Kovid-19 vaccine which was recently approved by British regulators.
The UK’s Medicine and Healthcare Products Regulatory Agency (MHRA) on Wednesday authorized the AstraZeneca-Oxford vaccine for deployment in the United Kingdom on the condition that the vaccine should be given in two doses, the first between 4 to 12 weeks after the second. Medication should be given. .
Here’s what you need to know about the vaccine:
Efficacy: In two different dosing regimens, the AstraZeneca-Oxford Kovid-19 vaccine showed efficacy of 90 percent and 62 percent. Participants who received two full doses within at least one month had 62 percent efficacy of the vaccine, and participants who received lower doses after the full dose had 90 percent efficacy.
Security: Lancet Publications, a leading medical journal, has confirmed that AZD1222 was well tolerated and no serious safety incidents related to the vaccine were confirmed. Safety data published are from over 20,000 participants, so far enrolled in four clinical trials in the UK and Brazil and South Africa.
Also read Expert panel of government approves AstraZeneca / Oxford Kovid-19 vaccine for emergency use
Storage: AstraZeneca-Oxford Kovid-19 Vaccine can be stored, transported, and handled at normal refrigerated conditions (2 ° C to 8 ° C) for at least six months.
Cost: SII Chief Executive Officer Adar Poonawala told Hindustan Times that the cost of Covidshield in India will be Rs 500-600.
Technology: AZD1222 is composed of a weak and modified version of adenovirus (a common cold virus) that causes infection in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. After vaccination, surface spike proteins are produced, instigating the immune system to attack the SARS-COV-2 virus if it subsequently infects the body.
STAY TUNED WITH US FOR MORE INTERESTING CONTENT ONLY ON DESINEW.XYZ